371,500.00
+9,500.00
+(2.62%)
At close: January 31 at 3:30:26 PM GMT+9
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | 2 | 2 |
| Avg. Estimate | 0 | 0 | 435.5 | 443 |
| Low Estimate | 0 | 0 | 381 | 245 |
| High Estimate | 0 | 0 | 490 | 641 |
| Year Ago EPS | -- | -- | -65 | 435.5 |
Revenue Estimate
| Currency in KRW | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 2 | 2 |
| Avg. Estimate | 40.8B | 17.7B | 84.5B | 108.9B |
| Low Estimate | 40.8B | 17.7B | 75B | 98B |
| High Estimate | 40.8B | 17.7B | 94B | 119.8B |
| Year Ago Sales | -- | -- | 96.52B | 84.5B |
| Sales Growth (year/est) | -- | -- | -12.46% | 28.88% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 435.5 | 443 |
| 7 Days Ago | 0 | 0 | 435.5 | 443 |
| 30 Days Ago | 0 | 0 | 435.5 | 443 |
| 60 Days Ago | 0 | 0 | 490 | 885.67 |
| 90 Days Ago | 0 | 0 | 216.33 | 961.33 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | 2 | -- |
| Down Last 7 Days | -- | -- | -- | 1 |
| Down Last 30 Days | -- | -- | -- | 2 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| 196170.KQ | -- | -- | 770.00% | 1.72% |
| S&P 500 | 9.91% | 10.33% | 14.01% | 13.75% |
Related Tickers
950160.KQ Kolon TissueGene, Inc.
28,700.00
-1.54%
R3X1.F Opus Genetics, Inc.
1.0420
-1.33%
141080.KQ LigaChem Biosciences Inc.
126,500.00
+3.27%
298380.KQ ABL Bio Inc.
36,350.00
+2.97%
9926.HK Akeso, Inc.
60.850
+1.76%
068270.KS Celltrion, Inc.
179,700.00
-0.28%
CLYM Climb Bio, Inc.
1.9000
-1.55%
BCAX Bicara Therapeutics Inc.
12.62
-2.25%
6855.HK Ascentage Pharma Group International
33.950
-3.00%
ACRV Acrivon Therapeutics, Inc.
6.07
+4.84%